# ROME (NCT04591431)

> The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04591431
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Fondazione per la Medicina Personalizzata
- Conditions: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
- Interventions: Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
- Enrollment: 400
- Primary outcome: OVERALL RESPONSE RATE (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 36
- YouTube: 6
- Podcasts: 6
- Bluesky threads: 3
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rome-nct04591431

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04591431", "email": "<work email>"}; the inbox owner confirms by the emailed link.